Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of YL202 versus docetaxel in previously treated EGFR-mutant non-squamous non-small cell lung cancer
CTR20260699Phase 3Active
- Sponsor
- MediLink Therapeutics
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of YL202 in non-small cell lung cancer (NSCLC), sponsored by MediLink Therapeutics. Started Mar 2026; status: active.
02
Drugs
YL202
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20260699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260699.